POM-V Prescription Required Companion Animal

Cerenia 10 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5008

What it's used for

Dogs • • • • recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine. Cats • by motion sickness. • Revised: February 2024 AN:...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Cerenia 10 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.

Dogs
•
•
•
•
recovery from general anaesthesia after use of the μ-opiate receptor agonist
morphine.
Cats
•
by motion sickness.
•

Revised: February 2024
AN: 02653/2022

None.

Dogs and cats:
Very common
(>1 animal / 10 animals
treated):
Injection site pain
1,2
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Anaphylactic-type reaction (e.g. allergic oedema,
urticaria, erythema, collapse NOS, dyspnoea,
pale mucous membranes)
Lethargy
Neurological disorder (e.g. ataxia, convulsion,
seizure, muscle tremor)
When injected subcutaneously.
A moderate to severe response can be observed in approximately one third of cats.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also section 16 of the
package leaflet for respective contact details.

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of Cerenia solution for injection against vomiting due to motion sickness is
not recommended.
Dogs:
Although Cerenia has been demonstrated to be effective in both the treatment and
prevention of emesis induced by chemotherapy, it was found more efficacious if used
preventively. Therefore, it is recommended to administer the antiemetic prior to
administration of the chemotherapeutic agent.
Cats:
The efficacy of Cerenia in reduction of nausea was demonstrated in studies using a
model (xylazine-induced nausea).

Special precautions for use in animals:
The safety of the veterinary medicinal product has not been established in dogs less
than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or
lactating dogs and cats. Use only according to the benefit-risk assessment by the
responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14-
day treatment period due to metabolic saturation, careful monitoring of liver function
and any adverse events should be implemented during long term treatment.
Cerenia should be used with caution in animals suffering from or with predisposition
for cardiac diseases as maropitant has affinity to Ca- and K-ion channels. Increases
of approximately 10% in the QT interval of the ECG were observed in a study on
healthy beagle dogs administered 8 mg/kg orally; however, such an increase is
unlikely to be of clinical significance.

Revised: February 2024
AN: 02653/2022
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
product at refrigerated temperature may reduce pain at injection.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
People with known hypersensitivity to maropitant should administer the veterinary
medicinal product with caution.
Wash hands after use. In case of accidental self-injection seek medical advice
immediately and show the package leaflet or the label to the physician. In laboratory
studies, maropitant has been shown to be a potential eye irritant. In the case of
accidental eye exposure, flush the eyes with plenty of water and seek medical
attention.
Special precautions for the protection of the environment:
Not applicable.

Cerenia should not be used concomitantly with Ca-channel antagonists as
maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly
bound medicines.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.